Controversias en dermatitis alérgica por contacto

Marta Patricia La Forgia; María Lucrecia Infante; Adriana Bassotti; Lucrecia Pilar Fortunato

doi:10.47196/da.v29i3.2418

Autores/as

Marta Patricia La Forgia Práctica Privada, Ciudad Autónoma de Buenos Aires, Argentina
María Lucrecia Infante Práctica Privada, Barcelona, España
Adriana Bassotti Universidad Nacional de Cuyo (UNC), Mendoza, Argentina
Lucrecia Pilar Fortunato Hospital Municipal de Agudos Dr. Leónidas Lucero, Bahía Blanca, Provincia de Buenos Aires, Argentina

DOI:

https://doi.org/10.47196/da.v29i3.2418

Palabras clave:

dermatitis alérgica por contacto, infancia, pruebas epicutáneas, parabenos, inmunosupresores

Resumen

El abordaje de la dermatitis alérgica por contacto plantea controversias en ciertas poblaciones como en los niños y en pacientes en tratamiento con inmunosupresores o biológicos. El posible beneficio resultante de la realización de pruebas epicutáneas amerita que, sin minimizar el desafío, se evalúe cada caso a la luz de la evidencia actual. En base a nuestra experiencia clínica y la revisión de la literatura podemos, además, encontrar respuestas frente a la descalificación de preservantes como los parabenos o frente a la sobrevaloración de los productos “naturales”.

Biografía del autor/a

Marta Patricia La Forgia, Práctica Privada, Ciudad Autónoma de Buenos Aires, Argentina

Médica Especialista en Dermatología y Alergia e Inmunología

María Lucrecia Infante, Práctica Privada, Barcelona, España

Médica Especialista en Dermatología

Adriana Bassotti, Universidad Nacional de Cuyo (UNC), Mendoza, Argentina

Médica Especialista en Dermatología Práctica Privada, Docente

Lucrecia Pilar Fortunato, Hospital Municipal de Agudos Dr. Leónidas Lucero, Bahía Blanca, Provincia de Buenos Aires, Argentina

Médica Especialista en Dermatología, Médica de Planta

Citas

I. Scheinman PL, Vocanson M, Thyssen JP, Johansen JD, et ál. Contact dermatitis. Nat Rev Dis Primers. 2021;7:38.

II. Neale H, Garza-Mayers AC, Tam I, Yu J. Pediatric allergic contact dermatitis. Part I: Clinical features and common contact allergens in children. J Am Acad Dermatol. 2021;84:235-244.

III. Bruckner AL, Weston WL, Morelli JG. Does sensitization to contact allergens begin in infancy? Pediatrics. 2000;105:e3.

IV. Low KY, Wallace M. Prevalence of potential contact allergens in baby cosmetic products. Clin Exp Dermatol. 2019;44:411-413.

V. Simonsen AB, Johansen JD, Deleuran M, Mortz CG, et ál. Contact allergy in children with atopic dermatitis: a systematic review. Br J Dermatol 2017;177:395-405.

VI. Jacob SE, Lipp MB, Suh E, Goldenberg A. Practice patterns of dermatologists in the pediatric contact dermatitis registry. Pediatr Dermatol. 2017;34:408-412.

VII. Neale H, Garza-Mayers AC, Tam I, Yu J. Pediatric allergic contact dermatitis. Part 2: Patch testing series, procedure, and unique scenarios. J Am Acad Dermatol. 2021;84:247-255.

VIII. Bruusgaard-Mouritsen MA, Johansen JD, Zachariae C, Kirkeby CS, et ál. Natural ingredients in cosmetic products. A suggestion for a screening series for skin allergy. Contact Dermatitis. 2020;83:251-270.

IX. Gilissen L, Huygens S, Goossens A. Allergic contact dermatitis caused by topical herbal remedies: importance of patch testing with the patients' own products. Contact Dermatitis. 2018;78:177-184.

X. de Groot AC. Propolis: a review of properties, applications, chemical composition, contact allergy, and other adverse effects. Dermatitis. 2013;24:263-282.

XI. Kwong HL, Lim SPR. Prevalence of propolis allergy in Singapore. JAAD Int. 2020;1:39-41.

XII. Groot AC, Schmidt E. Tea tree oil: contact allergy and chemical composition. Contact Dermatitis. 2016;75:129-143.

XIII. Martínez-Campayo N, Goday-Buján JJ, Fonseca-Capdevila E. Dermatitis alérgica de contacto por aceite de árbol del té. Acta Derm Venereol. 2020;111:787-788.

XIV. Błędzka D, Gromadzińska J, Wąsowicz W. Parabens. From environmental studies to human health. Environ Int. 2014;67:27-42.

XV. Fransway AF, Fransway PJ, Belsito DV, Warshaw EM, et ál. Parabens. Dermatitis. 2019;30:3-31.

XVI. Nowak K, Ratajczak-Wrona W, Górska M, Jabłońska E. Parabens and their effects on the endocrine system. Mol Cell Endocrinol. 2018;474:238-251.

XVII. Deza G, Giménez-Arnau AM. Allergic contact dermatitis in preservatives: current standing and future options. Curr Opin Allergy Clin Immunol. 2017;17:263-268.

XVIII. Nowak K, Jabłońska E, Ratajczak-Wrona W. Controversy around parabens: alternative strategies for preservative use in cosmetics and personal care products. Environ Res. 2021;198:10488.

XIX. Matwiejczuk N, Galicka A, Brzóska MM. Review of the safety of application of cosmetic products containing parabens. J Appl Toxicol. 2020; 40:176-210.

XX. Lazzarini R, Kawakami NT, Suzuki N, Hafner MFDS. Patch tests in patients using immunosuppressants and/or cytokine inhibitors: descriptive analysis of 16 cases. An Bras Dermatol. 2023;98:99-101.

XXI. Fowler JF Jr, Maibach HI, Zirwas M, Taylor JS, et ál. Effects of immunomodulatory agents on patch testing: expert opinion 2012. Dermatitis. 2012;23:301-303.

XXII. Kim N, Notik S, Gottlieb AB, Scheinman PL. Patch test results in psoriasis patients on biologics. Dermatitis. 2014;25:182-190.

XXIII. Todberg T, Zachariae C, Krustrup D, Skov L. The effect of anti-IL-17 treatment on the reaction to a nickel patch test in patients with allergic contact dermatitis. Int J Dermatol. 2019;58:e58-e61.

XXIV. Martínez-Mera C, González MA, Hospital M, Turrión-Merino L. Isothiazolinones in paint as a cause of airborne contact dermatitis in a patient with psoriasis receiving anti-interleukin-17 therapy. Contact Dermatitis. 2019;80:328-329.

XXV. Shah P, Milam EC, Lo Sicco KI, Cohen DE. Dupilumab for allergic contact dermatitis and implications for patch testing: irreconcilable differences. J Am Acad Dermatol. 2020;83: e215- e216.

XXVI. Jo CE, Mufti A, Sachdeva M, Pratt M, Yeung J. Effect of dupilumab on allergic contact dermatitis and patch testing. J Am Acad Dermatol. 2021;84:1772-1776.

XXVII. Mainville L, Veillette H, Houle MC. Sequential patch testing in a patient treated with dupilumab then with upadacitinib. Differences in patch test results as well as in disease control. Contact Dermatitis. 2023;88: 402‐404.

XXVIII. Johansson SG, Haahtela T, O'Byrne PM. Omalizumab and the immune system: an overview of preclinical and clinical data. Ann Allergy Asthma Immunol. 2002;89:132-138.

XXIX. Mufti A, Lu JD, Sachdeva M, Zaaroura H, et ál. Patch testing during immunosuppressive therapy: a systematic review. Dermatitis. 2021;32:365-374.